10-K/A: Day One Biopharmaceuticals Amends 10-K Filing to Correct Accounting Firm Consent and Audit Report References
10-K/A Amendment
Day One Biopharmaceuticals files an amendment to its 2024 annual report to correct errors in the independent accounting firm's consent and references within the audit reports.
Summary
- Day One Biopharmaceuticals filed an amendment (Form 10-K/A) to its original Form 10-K for the fiscal year ended December 31, 2024.
- The amendment corrects the consent filed as Exhibit 23.1, which contained an incorrect date, omitted reference to registration statements, and referenced the incorrect location of the accounting firm's office.
- The amendment also corrects references between the Audit Reports and the financial statements in Part II, Item 8 of the original filing.
- No other financial or other information in the original filing has been restated, amended, or updated.
- The amendment includes the entire text of Item 8 and Item 9A from the original filing, as well as new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.
- The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on June 30, 2024, was approximately $971.5 million.
- The number of shares of Registrant's Common Stock outstanding as of February 20, 2025 was 101,354,516.
Sentiment
Score: 7
Explanation: The document is neutral as it primarily addresses corrections to a previous filing. The financial results included are from the original filing and do not inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine amendment to correct administrative errors and does not reflect any changes in the company's business operations or financial condition.
Key Dates
| Date | Description |
|---|---|
| 2019-12-16 | Date of Takeda Asset Agreement |
| 2021-02-10 | Date of License agreement with Merck KGaA, Darmstadt, Germany |
| 2021-05-26 | Effective date of 2021 Employee Stock Purchase Plan |
| 2022-06-30 | Date of Sales Agreement |
| 2023-08-15 | Date of Research collaboration and license agreement with Sprint Bioscience AB |
| 2024-03-04 | Date of Amendment No. 1 to the License Agreement for RAF |
| 2024-04-23 | FDA approved OJEMDA |
| 2024-05-29 | Date of Asset Purchase Agreement |
| 2024-06-17 | Date of Exclusive License Agreement by and between MabCare Therapeutics and Day One Biopharmaceuticals, Inc. |
| 2024-07-23 | Date of Exclusive License Agreement by and between Day One Biopharmaceuticals, Inc. and Ipsen Pharma SAS |
| 2024-08-01 | Private Placement closed |
| 2024-12-03 | Viracta assigned the Viracta License Agreement to XOMA (US) LLC |
| 2024-12-31 | End of fiscal year |
| 2025-02-20 | Number of shares of Registrant's Common Stock outstanding |
| 2025-02-25 | Original Filing Date |
| 2025-03-06 | Date of Amendment No. 1 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.